How CBD and Low-Dose THC From Hemp Products Affect Drug Tests and the Body

In 60 healthy adults, daily CBD with trace THC amounts found in legal hemp products could trigger positive drug tests, with effects varying by THC dose level.

Wolinsky, David et al.·Journal of analytical toxicology·2025·Strong Evidenceclinical-trial
RTHC-07964Clinical TrialStrong Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
clinical-trial
Evidence
Strong Evidence
Sample
Not reported

What This Study Found

Even small amounts of THC in legal hemp CBD products (0.5-3.7 mg) could lead to positive drug tests after repeated use, with pharmacokinetic and pharmacodynamic effects varying by dose.

Key Numbers

60 healthy adults, 6 groups of 10, receiving 100 mg CBD with 0, 0.5, 1, 2, 2.8, or 3.7 mg THC. Includes 8-hour acute session plus 14-day outpatient exposure.

How They Did This

Controlled clinical study with 60 healthy adults self-administering 100 mg CBD with varying THC doses (0-3.7 mg) across an acute lab session and 14-day outpatient period, measuring pharmacokinetics and drug test results.

Why This Research Matters

Millions use legal hemp CBD products assuming they won't affect drug tests. This controlled study shows that even compliant hemp products can lead to positive tests, with real consequences for employment and legal situations.

The Bigger Picture

The legal distinction between hemp (≤0.3% THC) and marijuana creates a false sense of safety regarding drug testing. This study provides concrete data on how legal products can still cause problems in drug-testing scenarios.

What This Study Doesn't Tell Us

Controlled MCT oil formulation may differ from commercial products. 60 participants across 6 groups means only 10 per condition. Individual metabolism varies.

Questions This Raises

  • ?Should drug testing protocols be updated to account for legal hemp product use?
  • ?What THC threshold in hemp products truly prevents positive drug tests?

Trust & Context

Key Stat:
Evidence Grade:
Well-controlled clinical trial with multiple dose groups providing strong pharmacokinetic evidence, though moderate sample per group.
Study Age:
Recent study addressing a practical concern for the growing number of legal hemp CBD product users.
Original Title:
The Acute and Chronic Pharmacokinetics and Pharmacodynamics of Oral Cannabidiol (CBD) With and Without Low Doses of Delta-9-Tetrahydrocannabinol (Δ9-THC).
Published In:
Journal of analytical toxicology (2025)
Database ID:
RTHC-07964

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Can legal CBD products make you fail a drug test?

Yes — this study shows that even products meeting the legal THC limit (≤0.3%) can lead to positive drug tests after regular use, particularly at the higher end of allowable THC content.

How much THC does it take to trigger a positive test?

In this study, even 0.5 mg of THC alongside 100 mg CBD was tested. The risk increases with higher THC amounts and repeated daily use over the 14-day period.

Read More on RethinkTHC

Cite This Study

RTHC-07964·https://rethinkthc.com/research/RTHC-07964

APA

Wolinsky, David; Zamarripa, C Austin; Spindle, Tory R; Klausner, McKenna; Cone, Edward J; Winecker, Ruth E; Vikingsson, Svante; Flegel, Ronald R; Hayes, Eugene D; Davis, Lisa S; Kuntz, David; Bonn-Miller, Marcel; Bigelow, George E; Vandrey, Ryan. (2025). The Acute and Chronic Pharmacokinetics and Pharmacodynamics of Oral Cannabidiol (CBD) With and Without Low Doses of Delta-9-Tetrahydrocannabinol (Δ9-THC).. Journal of analytical toxicology. https://doi.org/10.1093/jat/bkaf075

MLA

Wolinsky, David, et al. "The Acute and Chronic Pharmacokinetics and Pharmacodynamics of Oral Cannabidiol (CBD) With and Without Low Doses of Delta-9-Tetrahydrocannabinol (Δ9-THC).." Journal of analytical toxicology, 2025. https://doi.org/10.1093/jat/bkaf075

RethinkTHC

RethinkTHC Research Database. "The Acute and Chronic Pharmacokinetics and Pharmacodynamics ..." RTHC-07964. Retrieved from https://rethinkthc.com/research/wolinsky-2025-the-acute-and-chronic

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.